EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of α-hemolysin activity of Staphylococcus aureus by theaflavin 3,3’-digallate

Anna Goc iD, Waldemar Sumera, Matthias Rath, Aleksandra Niedzwiecki

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0290904 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Anna Goc und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Dr. Rath Research Institute, San Jose, California, United States of America. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Staphylococcal Infections. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ongoing rise in antibiotic resistance, and a waning of the introduction of new antibiotics, has resulted in limited treatment options for bacterial infections, including these caused by methicillin-resistant Staphylococcus aureus , leaving the world in a post-antibiotic era. Here, we set out to examine mechanisms by which theaflavin 3,3’-digallate (TF3) might act as an anti-hemolytic compound. In the presented study, we found that TF3 has weak bacteriostatic and bactericidal effects on Staphylococcus aureus , and strong inhibitory effect towards the hemolytic activity of its α-hemolysin (Hla) including its production and secretion. A supportive SPR assay reinforced these results and further revealed binding of TF3 to Hla with KD = 4.57×10 −5 M. Interestingly, TF3 was also able to protect human primary keratinocytes from Hla-induced cell death, being at the same time non-toxic for them. Further analysis of TF3 properties revealed that TF3 blocked Hla-prompting immune reaction by inhibiting production and secretion of IL1β, IL6, and TNFα in vitro and in vivo , through affecting NFκB activity. Additionally, we observed that TF3 also markedly attenuated S . aureus -induced barrier disruption, by inhibiting Hla-triggered E-cadherin and ZO-1 impairment. Overall, by blocking activity of Hla, TF3 subsequently subdued the inflammation and protected the epithelial barrier, which is considered as beneficial to relieving skin injury.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsHumansStaphylococcus aureusHemolysin ProteinsAnti-Bacterial AgentsCatechinBiflavonoids

Substanzen

Hemolysin ProteinsAnti-Bacterial AgentstheaflavinCatechinBiflavonoids

Autor:innen und Institutionen

  • Department of Infectious Diseases, Dr. Rath Research Institute, San Jose, California, United States of America.

ORCID-Profile: Anna Goc

Zitieren

APA

Goc, A., Sumera, W., Rath, M., & Niedzwiecki, A. (2023). Inhibition of α-hemolysin activity of Staphylococcus aureus by theaflavin 3,3’-digallate. PLOS ONE. https://doi.org/10.1371/journal.pone.0290904

Vancouver

Goc A, Sumera W, Rath M, Niedzwiecki A. Inhibition of α-hemolysin activity of Staphylococcus aureus by theaflavin 3,3’-digallate. PLOS ONE. 2023. doi:10.1371/journal.pone.0290904

BibTeX
@article{Goc2023,
  author = {Goc, Anna and Sumera, Waldemar and Rath, Matthias and Niedzwiecki, Aleksandra},
  title = {Inhibition of α-hemolysin activity of Staphylococcus aureus by theaflavin 3,3’-digallate},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0290904}
}
Kostenlos starten →